Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity
Abstract
:1. Introduction
2. TGF-β Superfamily Members and Immunity
3. Expression of TGF-βs in Immune Cells
4. Synthesis of TGF-β3
5. TGF-β3 Signal Transduction
6. TGF-β3 in Immune Responses
6.1. Pro-Inflammatory Roles of TGF-β3
6.2. Anti-Inflammatory Roles of TGF-β3
7. TGF-β3 and Human Diseases
8. Concluding Remarks
Author Contributions
Funding
Conflicts of Interest
References
- Chen, W.; Ten Dijke, P. Immunoregulation by members of the TGFβ superfamily. Nat. Rev. Immunol. 2016, 16, 723–740. [Google Scholar] [CrossRef] [PubMed]
- Zhao, M.; Mishra, L.; Deng, C.X. The role of TGF-β/SMAD4 signaling in cancer. Int. J. Biol. Sci. 2018, 14, 123. [Google Scholar] [CrossRef] [PubMed]
- Wakefield, L.M.; Hill, C.S. Beyond TGFβ: Roles of other TGFβ superfamily members in cancer. Nat. Rev. Cancer 2013, 13, 328–341. [Google Scholar] [CrossRef] [PubMed]
- Meng, X.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-β: The master regulator of fibrosis. Nat. Rev. Nephrol. 2016, 12, 325–338. [Google Scholar] [CrossRef] [PubMed]
- Li, M.O.; Wan, Y.Y.; Sanjabi, S.; Robertson, A.K.; Flavell, R.A. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 2006, 24, 99–146. [Google Scholar] [CrossRef] [PubMed]
- Kulkarni, A.B.; Huh, C.G.; Becker, D.; Geiser, A.; Lyght, M.; Flanders, K.C.; Roberts, A.B.; Sporn, M.B.; Ward, J.M.; Karlsson, S. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 1993, 90, 770–774. [Google Scholar] [CrossRef] [PubMed]
- Shull, M.M.; Ormsby, I.; Kier, A.B.; Pawlowski, S.; Diebold, R.J.; Yin, M.; Allen, R.; Sidman, C.; Proetzel, G.; Calvin, D. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992, 359, 693–699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rubtsov, Y.P.; Rudensky, A.Y. TGFβ signalling in control of T-cell-mediated self-reactivity. Nat. Rev. Immunol. 2007, 7, 443–453. [Google Scholar] [CrossRef] [PubMed]
- Fujio, K.; Komai, T.; Inoue, M.; Morita, K.; Okamura, T.; Yamamoto, K. Revisiting the regulatory roles of the TGF-β family of cytokines. Autoimmun. Rev. 2016, 15, 917–922. [Google Scholar] [CrossRef] [PubMed]
- Okamura, T.; Morita, K.; Iwasaki, Y.; Inoue, M.; Komai, T.; Fujio, K.; Yamamoto, K. Role of TGF-β3 in the regulation of immune responses. Clin. Exp. Rheumatol. 2015, 33, 63–69. [Google Scholar]
- Roberts, A.B.; Anzano, M.A.; Lamb, L.C.; Smith, J.M.; Sporn, M.B. New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues. Proc. Natl. Acad. Sci. USA 1981, 78, 5339–5343. [Google Scholar] [CrossRef] [PubMed]
- Wrana, J.L. Signaling by the TGF-β Superfamily. Cold Spring Harb. Perspect. Biol. 2013, 5, a011197. [Google Scholar] [CrossRef] [PubMed]
- Roberts, A.B.; Lamb, L.C.; Newton, D.L.; Sporn, M.B.; De Larco, J.E.; Todaro, G.J. Transforming growth factors: Isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc. Natl. Acad. Sci. USA 1980, 77, 3494–3498. [Google Scholar] [CrossRef] [PubMed]
- Burt, D.W.; Law, A.S. Evolution of the transforming growth factor-β superfamily. Prog. Growth Factor Res. 1994, 5, 99–118. [Google Scholar] [CrossRef]
- Akhurst, R.J.; Hata, A. Targeting the TGFβ signalling pathway in disease. Nat. Rev. Drug Discov. 2012, 11, 790–811. [Google Scholar] [CrossRef] [PubMed]
- Matzuk, M.M.; Kumar, T.R.; Vassalli, A.; Bickenbach, J.R.; Roop, D.R.; Jaenisch, R.; Bradley, A. Functional analysis of activins during mammalian development. Nature 1995, 374, 354–356. [Google Scholar] [CrossRef] [PubMed]
- Zipori, D.; Barda-Saad, M. Role of activin A in negative regulation of normal and tumor B lymphocytes. J. Leukoc. Biol. 2001, 69, 867–873. [Google Scholar] [PubMed]
- Robson, N.C.; Phillips, D.J.; McAlpine, T.; Shin, A.; Svobodova, S.; Toy, T.; Pillay, V.; Kirkpatrick, N.; Zanker, D.; Wilson, K.; et al. Activin-A: A novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood 2008, 111, 2733–2743. [Google Scholar] [CrossRef] [PubMed]
- Hedger, M.P.; Drummond, A.E.; Robertson, D.M.; Risbridger, G.P.; de Kretser, D.M. Inhibin and activin regulate [3H]thymidine uptake by rat thymocytes and 3T3 cells in vitro. Mol. Cell. Endocrinol. 1989, 61, 133–138. [Google Scholar] [CrossRef]
- Hedger, M.P.; Clarke, L. Isolation of rat blood lymphocytes using a two-step Percoll density gradient. Effect of activin (erythroid differentiation factor) on peripheral T lymphocyte proliferation in vitro. J. Immunol. Methods 1993, 163, 133–136. [Google Scholar] [CrossRef]
- Huber, S.; Stahl, F.R.; Schrader, J.; Luth, S.; Presser, K.; Carambia, A.; Flavell, R.A.; Werner, S.; Blessing, M.; Herkel, J.; et al. Activin A Promotes the TGF-β-Induced Conversion of CD4+CD25− T Cells into Foxp3+ Induced Regulatory T Cells. J. Immunol. 2009, 182, 4633–4640. [Google Scholar] [CrossRef] [PubMed]
- Sakaguchi, S.; Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T. Regulatory T cells: How do they suppress immune responses? Int. Immunol. 2009, 21, 1105–1111. [Google Scholar] [CrossRef] [PubMed]
- Miyara, M.; Gorochov, G.; Ehrenstein, M.; Musset, L.; Sakaguchi, S.; Amoura, Z. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun. Rev. 2011, 10, 744–755. [Google Scholar] [CrossRef] [PubMed]
- Semitekolou, M.; Alissafi, T.; Aggelakopoulou, M.; Kourepini, E.; Kariyawasam, H.H.; Kay, A.B.; Robinson, D.S.; Lloyd, C.M.; Panoutsakopoulou, V.; Xanthou, G. Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease. J. Exp. Med. 2009, 206, 1769–1785. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hardy, C.L.; Rolland, J.M.; O’Hehir, R.E. The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy 2015, 45, 1510–1522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Soler Palacios, B.; Estrada-Capetillo, L.; Izquierdo, E.; Criado, G.; Nieto, C.; Municio, C.; González-Alvaro, I.; Sánchez-Mateos, P.; Pablos, J.L.; Corbí, A.L.; et al. Macrophages from the synovium of active rheumatoid arthritis exhibit an activin A-dependent pro-inflammatory profile. J. Pathol. 2015, 235, 515–526. [Google Scholar] [CrossRef] [PubMed]
- Ota, F.; Maeshima, A.; Yamashita, S.; Ikeuchi, H.; Kaneko, Y.; Kuroiwa, T.; Hiromura, K.; Ueki, K.; Kojima, I.; Nojima, Y. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2003, 48, 2442–2449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, R.N.; Green, J.; Wang, Z.; Deng, Y.; Qiao, M.; Peabody, M.; Zhang, Q.; Ye, J.; Yan, Z.; Denduluri, S.; et al. Bone Morphogenetic Protein (BMP) signaling in development and human diseases. Genes Dis. 2014, 1, 87–105. [Google Scholar] [CrossRef] [PubMed]
- Eixarch, H.; Calvo-Barreiro, L.; Montalban, X.; Espejo, C. Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation. Brain. Behav. Immun. 2018, 68, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Pluchino, S.; Zanotti, L.; Brambilla, E.; Rovere-Querini, P.; Capobianco, A.; Alfaro-Cervello, C.; Salani, G.; Cossetti, C.; Borsellino, G.; Battistini, L.; et al. Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS ONE 2009, 4, e5959. [Google Scholar] [CrossRef] [PubMed]
- Mausner-Fainberg, K.; Urshansky, N.; Regev, K.; Auriel, E.; Karni, A. Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 2013, 264, 91–99. [Google Scholar] [CrossRef] [PubMed]
- Tang, Y.; Ma, X.; Zhang, H.; Gu, Z.; Hou, Y.; Gilkeson, G.S.; Lu, L.; Zeng, X.; Sun, L. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin. Dev. Immunol. 2012, 2012, 826182. [Google Scholar] [CrossRef] [PubMed]
- Bramlage, C.P.; Häupl, T.; Kaps, C.; Ungethüm, U.; Krenn, V.; Pruss, A.; Müller, G.A.; Strutz, F.; Burmester, G.R. Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res. Ther. 2006, 8, R58. [Google Scholar] [CrossRef] [PubMed]
- Lories, R.J.; Derese, I.; Ceuppens, J.L.; Luyten, F.P. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum. 2003, 48, 2807–2818. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Travis, M.A.; Sheppard, D. TGF-β Activation and Function in Immunity. Annu. Rev. Immunol. 2014, 32, 51–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, M.O.; Wan, Y.Y.; Flavell, R.A. T cell-produced transforming growth factor-β1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26, 579–591. [Google Scholar] [CrossRef] [PubMed]
- Wan, Y.Y.; Flavell, R.A. “Yin-Yang” functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol. Rev. 2007, 220, 199–213. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, K.; Kitani, A.; Strober, W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor β. J. Exp. Med. 2001, 194, 629–644. [Google Scholar] [CrossRef] [PubMed]
- Roncarolo, M.G.; Levings, M.K.; Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 2001, 193, F5-9. [Google Scholar] [CrossRef] [PubMed]
- Roncarolo, M.G.; Bacchetta, R.; Bordignon, C.; Narula, S.; Levings, M.K. Type 1 T regulatory cells. Immunol. Rev. 2001, 182, 68–79. [Google Scholar] [CrossRef] [PubMed]
- Gutcher, I.; Donkor, M.K.; Ma, Q.; Rudensky, A.Y.; Flavell, R.A.; Li, M.O. Autocrine transforming growth factor-β1 promotes in vivo Th17 cell differentiation. Immunity 2011, 34, 396–408. [Google Scholar] [CrossRef] [PubMed]
- Worthington, J.J.; Kelly, A.; Smedley, C.; Bauché, D.; Campbell, S.; Marie, J.C.; Travis, M.A. Integrin αvβ8-Mediated TGF-β Activation by Effector Regulatory T Cells is Essential for Suppression of T-Cell-Mediated Inflammation. Immunity 2015, 42, 903–915. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dullaers, M.; Li, D.; Xue, Y.; Ni, L.; Gayet, I.; Morita, R.; Ueno, H.; Palucka, K.A.; Banchereau, J.; Oh, S. AT cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity 2009, 30, 120–129. [Google Scholar] [CrossRef] [PubMed]
- Sage, P.T.; Sharpe, A.H. T Follicular Regulatory Cells in the Regulation of B cell Responses. Trends Immunol. 2015, 36, 410–418. [Google Scholar] [CrossRef] [PubMed]
- Sage, P.T.; Sharpe, A.H. T follicular regulatory cells. Immunol. Rev. 2016, 271, 246–259. [Google Scholar] [CrossRef] [PubMed]
- Parekh, V.V.; Prasad, D.V.R.; Banerjee, P.P.; Joshi, B.N.; Kumar, A.; Mishra, G.C. B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: Role of TGF-β1. J. Immunol. 2003, 170, 5897–5911. [Google Scholar] [CrossRef] [PubMed]
- Bjarnadóttir, K.; Benkhoucha, M.; Merkler, D.; Weber, M.S.; Payne, N.L.; Bernard, C.C.; Molnarfi, N.; Lalive, P.H. B cell-derived transforming growth factor-β1 expression limits the induction phase of autoimmune neuroinflammation. Sci. Rep. 2016, 6, 34594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Molnarfi, N.; Bjarnadóttir, K.; Benkhoucha, M.; Juillard, C.; Lalive, P.H. Activation of human B cells negatively regulates TGF-β1 production. J. Neuroinflamm. 2017, 14, 13. [Google Scholar] [CrossRef] [PubMed]
- Gray, J.D.; Hirokawa, M.; Ohtsuka, K.; Horwitz, D.A. Generation of an inhibitory circuit involving CD8+ T cells, IL-2, and NK cell-derived TGF-β: Contrasting effects of anti-CD2 and anti-CD3. J. Immunol. 1998, 160, 2248–2254. [Google Scholar] [PubMed]
- Esplugues, E.; Sancho, D.; Vega-Ramos, J.; Martínez, C.; Syrbe, U.; Hamann, A.; Engel, P.; Sánchez-Madrid, F.; Lauzurica, P. Enhanced antitumor immunity in mice deficient in CD69. J. Exp. Med. 2003, 197, 1093–1106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, X.; Li, F.; Xie, L.; Crane, J.; Zhen, G.; Mishina, Y.; Deng, R.; Gao, B.; Chen, H.; Liu, S.; et al. Inhibition of overactive TGF-β attenuates progression of heterotopic ossification in mice. Nat. Commun. 2018, 9, 551. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Min, K.M.; Kim, P.H. Macrophage-derived TGF-β1 induces IgA isotype expression. Mol. Cells 2003, 16, 245–250. [Google Scholar] [PubMed]
- Morelli, A.E.; Zahorchak, A.F.; Larregina, A.T.; Colvin, B.L.; Logar, A.J.; Takayama, T.; Falo, L.D.; Thomson, A.W. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 2001, 98, 1512–1523. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lindstedt, K.A.; Wang, Y.; Shiota, N.; Saarinen, J.; Hyytiäinen, M.; Kokkonen, J.O.; Keski-Oja, J.; Kovanen, P.T. Activation of paracrine TGF-β1 signaling upon stimulation and degranulation of rat serosal mast cells: A novel function for chymase. FASEB J. 2001, 15, 1377–1388. [Google Scholar] [CrossRef] [PubMed]
- Kobayashi, T.; Iijima, K.; Kita, H. Marked airway eosinophilia prevents development of airway hyper-responsiveness during an allergic response in IL-5 transgenic mice. J. Immunol. 2003, 170, 5756–5763. [Google Scholar] [CrossRef] [PubMed]
- Chu, V.T.; Beller, A.; Rausch, S.; Strandmark, J.; Zänker, M.; Arbach, O.; Kruglov, A.; Berek, C. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity 2014, 40, 582–593. [Google Scholar] [CrossRef] [PubMed]
- Weller, P.F.; Spencer, L.A. Functions of tissue-resident eosinophils. Nat. Rev. Immunol. 2017, 17, 746–760. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Xia, P.; Chen, Y.; Qu, Y.; Xiong, Z.; Ye, B.; Du, Y.; Tian, Y.; Yin, Z.; Xu, Z.; et al. Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation. Cell 2017, 171, 201–216. [Google Scholar] [CrossRef] [PubMed]
- Okamura, T.; Sumitomo, S.; Morita, K.; Iwasaki, Y.; Inoue, M.; Nakachi, S.; Komai, T.; Shoda, H.; Miyazaki, J.; Fujio, K.; et al. TGF-β3-expressing CD4(+)CD25(−)LAG3(+) regulatory T cells control humoral immune responses. Nat. Commun. 2015, 6, 6329. [Google Scholar] [CrossRef] [PubMed]
- Morita, K.; Okamura, T.; Inoue, M.; Komai, T.; Teruya, S.; Iwasaki, Y.; Sumitomo, S.; Shoda, H.; Yamamoto, K.; Fujio, K. Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production. Proc. Natl. Acad. Sci. USA 2016, 113, E8131–E8140. [Google Scholar] [CrossRef] [PubMed]
- Zhu, B.; Symonds, A.L.; Martin, J.E.; Kioussis, D.; Wraith, D.C.; Li, S.; Wang, P. Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. J. Exp. Med. 2008, 205, 2295–2307. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Myouzen, K.; Kochi, Y.; Shimane, K.; Fujio, K.; Okamura, T.; Okada, Y.; Suzuki, A.; Atsumi, T.; Ito, S.; Takada, K.; et al. Regulatory polymorphisms in EGR2 are associated with susceptibility to systemic lupus erythematosus. Hum. Mol. Genet. 2010, 19, 2313–2320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Okamura, T.; Fujio, K.; Shibuya, M.; Sumitomo, S.; Shoda, H.; Sakaguchi, S.; Yamamoto, K. CD4+CD25−LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc. Natl. Acad. Sci. USA 2009, 106, 13974–13979. [Google Scholar] [CrossRef] [PubMed]
- Okamura, T.; Yamamoto, K.; Fujio, K. Early Growth Response Gene 2-Expressing CD4+LAG3+ Regulatory T Cells: The Therapeutic Potential for Treating Autoimmune Diseases. Front. Immunol. 2018, 9. [Google Scholar] [CrossRef] [PubMed]
- Dijke, P.; Arthur, H.M. Extracellular control of TGFβ signalling in vascular development and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 857–869. [Google Scholar] [CrossRef] [PubMed]
- Annes, J.P.; Munger, J.S.; Rifkin, D.B. Making sense of latent TGFβ activation. J. Cell Sci. 2003, 116, 217–224. [Google Scholar] [CrossRef] [PubMed]
- Robertson, I.B.; Horiguchi, M.; Zilberberg, L.; Dabovic, B.; Hadjiolova, K.; Rifkin, D.B. Latent TGF-β-binding proteins. Matrix Biol. 2015, 47, 44–53. [Google Scholar] [CrossRef] [PubMed]
- Saharinen, J.; Keski-Oja, J. Specific sequence motif of 8-Cys repeats of TGF-β binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-β. Mol. Biol. Cell 2000, 11, 2691–2704. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Ali, T.; Todorovic, V.; O’Leary, J.M.; Kristina Downing, A.; Rifkin, D.B. Amino Acid Requirements for Formation of the TGF-β-Latent TGF-β Binding Protein Complexes. J. Mol. Biol. 2005, 345, 175–186. [Google Scholar] [CrossRef] [PubMed]
- Yoshinaga, K.; Obata, H.; Jurukovski, V.; Mazzieri, R.; Chen, Y.; Zilberberg, L.; Huso, D.; Melamed, J.; Prijatelj, P.; Todorovic, V.; et al. Perturbation of transforming growth factor (TGF)-β1 association with latent TGF-β binding protein yields inflammation and tumors. Proc. Natl. Acad. Sci. USA 2008, 105, 18758–18763. [Google Scholar] [CrossRef] [PubMed]
- Rifkin, D.B.; Rifkin, W.J.; Zilberberg, L. LTBPs in biology and medicine: LTBP diseases. Matrix Biol. 2017. [Google Scholar] [CrossRef] [PubMed]
- Shi, M.; Zhu, J.; Wang, R.; Chen, X.; Mi, L.; Walz, T.; Springer, T.A. Latent TGF-β structure and activation. Nature 2011, 474, 343–349. [Google Scholar] [CrossRef] [PubMed]
- Yang, Z.; Mu, Z.; Dabovic, B.; Jurukovski, V.; Yu, D.; Sung, J.; Xiong, X.; Munger, J.S. Absence of integrin-mediated TGFβ1 activation in vivo recapitulates the phenotype of TGFβ1-null mice. J. Cell Biol. 2007, 176, 787–793. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, J.; Dong, X.; Zhao, B.; Li, J.; Lu, C.; Springer, T.A. Atypical interactions of integrin αVβ8with pro-TGF-β1. Proc. Natl. Acad. Sci. USA 2017, 114, E4168–E4174. [Google Scholar] [CrossRef] [PubMed]
- Aluwihare, P.; Mu, Z.; Zhao, Z.; Yu, D.; Weinreb, P.H.; Horan, G.S.; Violette, S.M.; Munger, J.S. Mice that lack activity of αvβ6- and αvβ8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice. J. Cell Sci. 2009, 122, 227–232. [Google Scholar] [CrossRef] [PubMed]
- Travis, M.A.; Reizis, B.; Melton, A.C.; Masteller, E.; Tang, Q.; Proctor, J.M.; Wang, Y.; Bernstein, X.; Huang, X.; Reichardt, L.F.; et al. Loss of integrin α(v)β8 on dendritic cells causes autoimmunity and colitis in mice. Nature 2007, 449, 361–365. [Google Scholar] [CrossRef] [PubMed]
- Massague, J. TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630. [Google Scholar] [CrossRef] [PubMed]
- Wrighton, K.H.; Lin, X.; Feng, X.H. Phospho-control of TGF-β superfamily signaling. Cell Res. 2009, 19, 8–20. [Google Scholar] [CrossRef] [PubMed]
- Goumans, M.J.; Valdimarsdottir, G.; Itoh, S.; Lebrin, F.; Larsson, J.; Mummery, C.; Karlsson, S.; ten Dijke, P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol. Cell 2003, 12, 817–828. [Google Scholar] [CrossRef]
- Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003, 425, 577–584. [Google Scholar] [CrossRef] [PubMed]
- Curado, F.; Spuul, P.; Egana, I.; Rottiers, P.; Daubon, T.; Veillat, V.; Duhamel, P.; Leclercq, A.; Gontier, E.; Genot, E. ALK5 and ALK1 Play Antagonistic Roles in Transforming Growth Factor β-Induced Podosome Formation in Aortic Endothelial Cells. Mol. Cell. Biol. 2014, 34, 4389–4403. [Google Scholar] [CrossRef] [PubMed]
- Goumans, M.J.; Liu, Z.; ten Dijke, P. TGF-β signaling in vascular biology and dysfunction. Cell Res. 2009, 19, 116–127. [Google Scholar] [CrossRef] [PubMed]
- Cheifetz, S.; Bellón, T.; Calés, C.; Vera, S.; Bernabeu, C.; Massagué, J.; Letarte, M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. Biol. Chem. 1992, 267, 19027–19030. [Google Scholar] [PubMed]
- Piek, E.; Moustakas, A.; Kurisaki, A.; Heldin, C.H.; ten Dijke, P. TGF-(β) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J. Cell Sci. 1999, 112 Pt 24, 4557–4568. [Google Scholar] [PubMed]
- Dudas, M.; Nagy, A.; Laping, N.J.; Moustakas, A.; Kaartinen, V. Tgf-β3-induced palatal fusion is mediated by Alk-5/Smad pathway. Dev. Biol. 2004, 266, 96–108. [Google Scholar] [CrossRef] [PubMed]
- Lane, J.; Yumoto, K.; Azhar, M.; Ninomiya-Tsuji, J.; Inagaki, M.; Hu, Y.; Deng, C.X.; Kim, J.; Mishina, Y.; Kaartinen, V. Tak1, Smad4 and Trim33 redundantly mediate TGF-β3 signaling during palate development. Dev. Biol. 2015, 398, 231–241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsuchida, Y.; Sumitomo, S.; Ishigaki, K.; Suzuki, A.; Kochi, Y.; Tsuchiya, H.; Ota, M.; Komai, T.; Inoue, M.; Morita, K.; et al. TGF-β3 Inhibits Antibody Production by Human B Cells. PLoS ONE 2017, 12, e0169646. [Google Scholar] [CrossRef] [PubMed]
- Bakkebø, M.; Huse, K.; Hilden, V.I.; Smeland, E.B.; Oksvold, M.P. TGF-β-induced growth inhibition in B-cell lymphoma correlates with Smad1/5 signalling and constitutively active p38 MAPK. BMC Immunol. 2010, 11, 57. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.; Awasthi, A.; Yosef, N.; Quintana, F.J.; Xiao, S.; Peters, A.; Wu, C.; Kleinewietfeld, M.; Kunder, S.; Hafler, D.A.; et al. Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 2012, 13, 991–999. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- David, C.J.; Massagué, J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 2018. [Google Scholar] [CrossRef] [PubMed]
- Kaartinen, V.; Voncken, J.W.; Shuler, C.; Warburton, D.; Bu, D.; Heisterkamp, N.; Groffen, J. Abnormal lung development and cleft palate in mice lacking TGF-β 3 indicates defects of epithelial-mesenchymal interaction. Nat. Genet. 1995, 11, 415–421. [Google Scholar] [CrossRef] [PubMed]
- Proetzel, G.; Pawlowski, S.A.; Wiles, M.V.; Yin, M.; Boivin, G.P.; Howles, P.N.; Ding, J.; Ferguson, M.W.; Doetschman, T. Transforming growth factor-β3 is required for secondary palate fusion. Nat. Genet. 1995, 11, 409–414. [Google Scholar] [CrossRef] [PubMed]
- Chikuma, S.; Suita, N.; Okazaki, I.M.; Shibayama, S.; Honjo, T. TRIM28 prevents autoinflammatory T cell development in vivo. Nat. Immunol. 2012, 13, 596–603. [Google Scholar] [CrossRef] [PubMed]
- McKams, S.C.; Letterio, J.J.; Kaminski, N.E. Concentration-dependent bifunctional effect of TGF-beta 1 on immunoglobulin production: A role for Smad3 inIgA production in vitro. Int. Immunopharmacol. 2003, 3, 1761–1774. [Google Scholar]
- McIntyre, T.M.; Klinman, D.R.; Rothman, P.; Lugo, M.; Dasch, J.R.; Mond, J.J.; Snapper, C.M. Transforming growth factor β1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J. Exp. Med. 1993, 177, 1031–1037. [Google Scholar] [CrossRef] [PubMed]
- Komai, T.; Inoue, M.; Okamura, T.; Morita, K.; Iwasaki, Y.; Sumitomo, S.; Shoda, H.; Yamamoto, K.; Fujio, K. Transforming growth factor-β and interleukin-10 synergistically regulate humoral immunity via modulating metabolic signals. Front. Immunol. 2018, 9, 1364. [Google Scholar] [CrossRef] [PubMed]
- Hall, B.E.; Wankhade, U.D.; Konkel, J.E.; Cherukuri, K.; Nagineni, C.N.; Flanders, K.C.; Arany, P.R.; Chen, W.; Rane, S.G.; Kulkarni, A.B. Transforming growth factor-β3 (TGF-β3) knock-in ameliorates inflammation due to TGF-β1 deficiency while promoting glucose tolerance. J. Biol. Chem. 2013, 288, 32074–32092. [Google Scholar] [CrossRef] [PubMed]
- Shah, S.; Qiao, L. Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF-β3. Eur. J. Immunol. 2008, 38, 2488–2498. [Google Scholar] [CrossRef] [PubMed]
- Gorelik, L.; Constant, S.; Flavell, R.A. Mechanism of transforming growth factor β-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 2002, 195, 1499–1505. [Google Scholar] [CrossRef] [PubMed]
- Gorelik, L.; Fields, P.E.; Flavell, R.A. Cutting edge: TGF-β inhibits Th type 2 development through inhibition of GATA-3 expression. J. Immunol. 2000, 165, 4773–4777. [Google Scholar] [CrossRef] [PubMed]
- Viel, S.; Marçais, A.; Guimaraes, F.S.; Loftus, R.; Rabilloud, J.; Grau, M.; Degouve, S.; Djebali, S.; Sanlaville, A.; Charrier, E.; et al. TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 2016, 9, ra19. [Google Scholar] [CrossRef] [PubMed]
- Werner, F.; Jain, M.K.; Feinberg, M.W.; Sibinga, N.E.; Pellacani, A.; Wiesel, P.; Chin, M.T.; Topper, J.N.; Perrella, M.A.; Lee, M.E. Transforming Growth Factor-β1 Inhibition of Macrophage Activation is Mediated via Smad3. J. Biol. Chem. 2000, 275, 36653–36658. [Google Scholar] [CrossRef] [PubMed]
- Cazac, B.B.; Roes, J. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 2000, 13, 443–451. [Google Scholar] [CrossRef]
- Roes, J.; Choi, B.K.; Cazac, B.B. Redirection of B cell responsiveness by transforming growth factor β receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 7241–7246. [Google Scholar] [CrossRef] [PubMed]
- Victora, G.D.; Schwickert, T.A.; Fooksman, D.R.; Kamphorst, A.O.; Meyer-Hermann, M.; Dustin, M.L.; Nussenzweig, M.C. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 2010, 143, 592–605. [Google Scholar] [CrossRef] [PubMed]
- Kräutler, N.J.; Suan, D.; Butt, D.; Bourne, K.; Hermes, J.R.; Chan, T.D.; Sundling, C.; Kaplan, W.; Schofield, P.; Jackson, J.; et al. Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells. J. Exp. Med. 2017, 214, 1259–1267. [Google Scholar] [CrossRef] [PubMed]
- Saxena, A.; Khosraviani, S.; Noel, S.; Mohan, D.; Donner, T.; Hamad, A.R. Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 2015, 74, 27–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bartee, E.; McFadden, G. Cytokine synergy: An underappreciated contributor to innate anti-viral immunity. Cytokine 2013, 63, 237–240. [Google Scholar] [CrossRef] [PubMed]
- Yokogawa, M.; Takaishi, M.; Nakajima, K.; Kamijima, R.; Fujimoto, C.; Kataoka, S.; Terada, Y.; Sano, S. Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: A new model of systemic lupus erythematosus. Arthritis Rheumatol. 2014, 66, 694–706. [Google Scholar] [CrossRef] [PubMed]
- Bertoli-Avella, A.M.; Gillis, E.; Morisaki, H.; Verhagen, J.M.A.; de Graaf, B.M.; van de Beek, G.; Gallo, E.; Kruithof, B.P.T.; Venselaar, H.; Myers, L.A.; et al. Mutations in a TGF-β Ligand, TGFB3, Cause Syndromic Aortic Aneurysms and Dissections. J. Am. Coll. Cardiol. 2015, 65, 1324–1336. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lafyatis, R. Transforming growth factor β—At the centre of systemic sclerosis. Nat. Rev. Rheumatol. 2014, 10, 706–719. [Google Scholar] [CrossRef] [PubMed]
- Christmann, R.B.; Sampaio-Barros, P.; Stifano, G.; Borges, C.L.; de Carvalho, C.R.; Kairalla, R.; Parra, E.R.; Spira, A.; Simms, R.; Capellozzi, V.L.; et al. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 2014, 66, 714–725. [Google Scholar] [CrossRef] [PubMed]
- Dziadzio, M.; Smith, R.E.; Abraham, D.J.; Black, C.M.; Denton, C.P. Circulating levels of active transforming growth factor β1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology 2005, 44, 1518–1524. [Google Scholar] [CrossRef] [PubMed]
- Higashiyama, H.; Yoshimoto, D.; Kaise, T.; Matsubara, S.; Fujiwara, M.; Kikkawa, H.; Asano, S.; Kinoshita, M. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis. Exp. Mol. Pathol. 2007, 83, 39–46. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; McCormick, L.L.; Gilliam, A.C. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J. Investig. Dermatol. 2003, 121, 713–719. [Google Scholar] [CrossRef] [PubMed]
- Denton, C.P.; Merkel, P.A.; Furst, D.E.; Khanna, D.; Emery, P.; Hsu, V.M.; Silliman, N.; Streisand, J.; Powell, J.; Åkesson, A.; et al. Scleroderma Clinical Trials Consortium Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007, 56, 323–333. [Google Scholar] [CrossRef] [PubMed]
- Rice, L.M.; Padilla, C.M.; McLaughlin, S.R.; Mathes, A.; Ziemek, J.; Goummih, S.; Nakerakanti, S.; York, M.; Farina, G.; Whitfield, M.L.; et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Investig. 2015, 125, 2795–2807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gourh, P.; Remmers, E.F.; Satpathy, A.; Boyden, S.; Morgan, N.D.; Shah, A.A.; Adeyemo, A.; Bentley, A.; Carns, M.A.; Chandrasekharappa, S.C.; et al. Transforming Growth Factor β3 (TGFB3)—A Novel Systemic Sclerosis Susceptibility Locus Involved in Fibrosis and Th17 Cell Development Identified By Genome-Wide Association Study in African Americans from the Genome Research in African American Scleroderma Patients Consortium. Arthritis Rheumatol. 2017, 69 (Suppl. 10). [Google Scholar] [CrossRef]
- Saxena, V.; Lienesch, D.W.; Zhou, M.; Bommireddy, R.; Azhar, M.; Doetschman, T.; Singh, R.R. Dual roles of immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunity-mediated organ damage. J. Immunol. 2008, 180, 1903–1912. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, J.; Woodworth, L.; Smith, K.; Coco, J.; Vitsky, A.; McPherson, J. Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-β1 in the MRL/LPR lupus mouse model. Lupus 2008, 17, 822–831. [Google Scholar] [CrossRef] [PubMed]
- Hammad, A.M.; Youssef, H.M.; El-Arman, M.M. Transforming growth factor β 1 in children with systemic lupus erythematosus: A possible relation with clinical presentation of lupus nephritis. Lupus 2006, 15, 608–612. [Google Scholar] [CrossRef] [PubMed]
- Becker-Merok, A.; Eilertsen, G.Ø.; Nossent, J.C. Levels of transforming growth factor-β are low in systemic lupus erythematosus patients with active disease. J. Rheumatol. 2010, 37, 2039–2045. [Google Scholar] [CrossRef] [PubMed]
- Elbeldi-Ferchiou, A.; Ben Ahmed, M.; Smiti-Khanfir, M.; Houman, M.H.; Abdeladhim, M.; Belhadj Hmida, N.; Cerf-Bensussan, N.; Louzir, H. Resistance to exogenous TGF-β effects in patients with systemic lupus erythematosus. J. Clin. Immunol. 2011, 31, 574–583. [Google Scholar] [CrossRef] [PubMed]
- Severin, M.E.; Lee, P.W.; Liu, Y.; Selhorst, A.J.; Gormley, M.G.; Pei, W.; Yang, Y.; Guerau-de-Arellano, M.; Racke, M.K.; Lovett-Racke, A.E. MicroRNAs targeting TGFβ signalling underlie the regulatory T cell defect in multiple sclerosis. Brain 2016, 139, 1747–1761. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Calabresi, P.A.; Fields, N.S.; Maloni, H.W.; Hanham, A.; Carlino, J.; Moore, J.; Levin, M.C.; Dhib-Jalbut, S.; Tranquill, L.R.; Austin, H.; et al. Phase 1 trial of transforming growth factor β2 in chronic progressive MS. Neurology 1998, 51, 289–292. [Google Scholar] [CrossRef] [PubMed]
- Lee, P.W.; Severin, M.E.; Lovett-Racke, A.E. TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis. Eur. J. Immunol. 2017, 47, 446–453. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aschner, Y.; Downey, G.P. Transforming Growth Factor-β: Master Regulator of the Respiratory System in Health and Disease. Am. J. Respir. Cell Mol. Biol. 2016, 54, 647–655. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walton, K.L.; Johnson, K.E.; Harrison, C.A. Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis. Front. Pharmacol. 2017, 8, 461. [Google Scholar] [CrossRef] [PubMed]
- Ferguson, M.W.; Duncan, J.; Bond, J.; Bush, J.; Durani, P.; So, K.; Taylor, L.; Chantrey, J.; Mason, T.; James, G.; et al. Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet 2009, 373, 1264–1274. [Google Scholar] [CrossRef]
- De Gramont, A.; Faivre, S.; Raymond, E. Novel TGF-β inhibitors ready for prime time in onco-immunology. Oncoimmunology 2017, 6, e1257453. [Google Scholar] [CrossRef] [PubMed]
- Harjes, U. Immunotherapy: Tear down this wall. Nat. Rev. Immunol. 2018, 18, 221. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Komai, T.; Okamura, T.; Inoue, M.; Yamamoto, K.; Fujio, K. Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity. Int. J. Mol. Sci. 2018, 19, 2261. https://doi.org/10.3390/ijms19082261
Komai T, Okamura T, Inoue M, Yamamoto K, Fujio K. Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity. International Journal of Molecular Sciences. 2018; 19(8):2261. https://doi.org/10.3390/ijms19082261
Chicago/Turabian StyleKomai, Toshihiko, Tomohisa Okamura, Mariko Inoue, Kazuhiko Yamamoto, and Keishi Fujio. 2018. "Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity" International Journal of Molecular Sciences 19, no. 8: 2261. https://doi.org/10.3390/ijms19082261